CDEK
← All drugs Report issue

linzagolix

Small moleculeexperimental

Linzagolix, sold under the brand name Yselty, is a medication used in the treatment of uterine fibroids and endometriosis. Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist developed by Kissei Pharmaceutical and ObsEva. — Wikipedia

Clinical trial activity

9 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
7
Phase 3
6
Phase 4
0

Earliest trial started May 23, 2019 (NCT03986944)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F
Mol. weight
508.43 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05738382Phase 2Aug 31, 2023Government of China, Sun Yat-Sen University
NCT05894135Phase 3Jul 14, 2023Fudan University, Government of China
NCT05620355Phase 3Dec 31, 2022Fudan University, Government of China
NCT04372121Phase 3Mar 23, 2020ObsEva SA
NCT04335591Phase 3Mar 5, 2020ObsEva SA
NCT03992846Phase 3Jun 13, 2019ObsEva SA
NCT03961932Phase 1May 31, 2019ObsEva SA
NCT03962049Phase 1May 31, 2019ObsEva SA
NCT03986944Phase 3May 23, 2019ObsEva SA
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ObsEva SAFor profit6622019
Government of ChinaGovernment3322022
Fudan UniversityAcademic/Hospital2012022
Sun Yat-Sen UniversityAcademic/Hospital1012023
4 organizations
Page 1 / 1